We next assessed the effects of GR activation on the viability of ER+ patient-derived xenograft tumor organoids (PDXO) cultured in Matrigel ex vivo by treating PDXOs with Dex or vehicle for 10 days (Fig. 2C). The gene discussed is NR3C1; the disease is neoplasm.